[113]
Novopharm's, and Mr. Windross', approach to this matter was based upon the premise that s. 6(8) of the
Regulations
provides a statutory mandate for the blanket protection of documents and information disclosed under s. 6(7). Mr. Windross' evidence and his general assertions are geared to this approach. But once it is concluded that s. 6(8) does not provide such blanket mandatory coverage, and that the normal
Sierra Club
test has to be satisfied, the shortcomings of such an approach become immediately evident.